BioAegis Therapeutics is a clinical stage company, developing novel protein replacement therapies targeted at saving lives. The portfolio is based on the endogenous human protein, plasma gelsolin (pGSN). Plasma gelsolin, recently discovered to be a key component of innate immunity, provides an immunotherapeutic approach to fighting pathogens. Additionally, the protein protects end organs against the effects of an uncontrolled and cascading inflammatory response in numerous diseases.
